Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Share-based Compensation (2016 - 2025)

BioCorRx's Share-based Compensation history spans 13 years, with the latest figure at $16060.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 113.34% year-over-year to $16060.0; the TTM value through Sep 2025 reached $1.3 million, up 793.86%, while the annual FY2024 figure was $1.2 million, 340.08% up from the prior year.
  • Share-based Compensation for Q3 2025 was $16060.0 at BioCorRx, down from $30715.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.1 million in Q4 2024 and bottomed at -$172429.0 in Q4 2022.
  • The 5-year median for Share-based Compensation is $34489.0 (2023), against an average of $95554.2.
  • The largest YoY upside for Share-based Compensation was 2803.75% in 2024 against a maximum downside of 842.76% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $43175.0 in 2021, then tumbled by 499.37% to -$172429.0 in 2022, then surged by 122.19% to $38263.0 in 2023, then surged by 2803.75% to $1.1 million in 2024, then tumbled by 98.55% to $16060.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Share-based Compensation are $16060.0 (Q3 2025), $30715.0 (Q2 2025), and $151257.0 (Q1 2025).